Melflufen and dexamethasone versus pomalidomide and dexamethasone in relapsed refractory multiple myeloma

Share :
Published: 30 Apr 2024
Views: 39
Dr Fredrik Schjesvold - Oslo Myeloma Center, Oslo, Norway

Dr Fredrik Schjesvold speaks to ecancer about results from the OCEAN study that he presented at EMN 2024.

He explains that this is a phase III study where patients were randomised 1:1 between melflufen and dexamethasone versus pomalidomide and dexamethasone with the primary endpoint being PFS.

Dr Schjesvold reports that the results were quite complicated. Initial findings showed an improvement in PFS with melflufen and dexamethasone but a slight improvement in OS with pomalidomide and dexamethasone.

However a closer look at the data showed that non-transplant patients were the ones seeing the greatest benefit from the new treatment - leading to an approval of the drug in non-transplant patients.